open access

Vol 78, No 6 (2010)
REVIEWS
Published online: 2010-10-29
Submitted: 2013-02-22
Get Citation

Consolidation therapy in advanced non-small cell lung cancer

Renata Duchnowska
Pneumonol Alergol Pol 2010;78(6):439-444.

open access

Vol 78, No 6 (2010)
REVIEWS
Published online: 2010-10-29
Submitted: 2013-02-22

Abstract

Standard management of advanced non-small cell lung cancer includes palliative chemotherapy, but its efficacy is modest. In most cases a few cycles of palliative chemotherapy are administered, as there is no evidence of benefit associated with prolonged treatment. Recently, there is an interest in a new approach including treatment continuation using cytotoxic compounds of proved efficacy in second-line treatment, such as docetaxel and pemetrexed, or targeted agents (erlotinib, gefitinib, cetuximab and bevacizumab). This review presents the current knowledge on this therapeutic strategy including the results of most relevant phase III studies and their metaanalyses.
Pneumonol. Alergol. Pol. 2010; 78, 6: 439-444

Abstract

Standard management of advanced non-small cell lung cancer includes palliative chemotherapy, but its efficacy is modest. In most cases a few cycles of palliative chemotherapy are administered, as there is no evidence of benefit associated with prolonged treatment. Recently, there is an interest in a new approach including treatment continuation using cytotoxic compounds of proved efficacy in second-line treatment, such as docetaxel and pemetrexed, or targeted agents (erlotinib, gefitinib, cetuximab and bevacizumab). This review presents the current knowledge on this therapeutic strategy including the results of most relevant phase III studies and their metaanalyses.
Pneumonol. Alergol. Pol. 2010; 78, 6: 439-444
Get Citation

Keywords

non-small cell lung cancer; chemotherapy; maintenance therapy; docetaxel; pemetrexed; targeted therapies

About this article
Title

Consolidation therapy in advanced non-small cell lung cancer

Journal

Advances in Respiratory Medicine

Issue

Vol 78, No 6 (2010)

Pages

439-444

Published online

2010-10-29

Bibliographic record

Pneumonol Alergol Pol 2010;78(6):439-444.

Keywords

non-small cell lung cancer
chemotherapy
maintenance therapy
docetaxel
pemetrexed
targeted therapies

Authors

Renata Duchnowska

References (32)
  1. Booton R, Thatcher N. Chemotherapy in advanced nonsmall cell lung cancer: indication, intensity, and duration. Curr Opin Oncol. 2002; 14(2): 191–198.
  2. Socinski MA, Baggstrom MQ, Hensing TA. Duration of therapy in advanced, metastatic non-small-cell lung cancer. Clin Adv Hematol Oncol. 2003; 1(1): 33–38.
  3. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004; 350(4): 379–392.
  4. Socinski MA. Clinical issues in the management of non-small-cell lung cancer and the role of platinum-based therapy. Clin Lung Cancer. 2004; 5(5): 274–289.
  5. Vergnenègre A. [Stage IV non-small cell lung cancer. Duration of chemotherapy for locally advanced non small cell lung cancers]. Rev Mal Respir. 2006; 23(5 Pt 3): 16S72–16S77.
  6. Lustberg MB, Edelman MJ. Optimal duration of chemotherapy in advanced non-small cell lung cancer. Curr Treat Options Oncol. 2007; 8(1): 38–46.
  7. Barata FJ, Parente B, Teixeira N, et al. Optimal duration of chemotherapy in non-small-cell lung cancer: multicenter, randomized, prospective clinical trial comparing 4 vs 6 cycles of carboplatin and gemcitabine. 2007; 2: S666 (supl. J. Thorac. Oncol. 2007; 2(S666): (supl.; abstr. P2–235).
  8. Belani CP, Brodowicz T, Ciuleanu TE, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009; 374(9699): 1432–1440.
  9. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2009; 27(4): 591–598.
  10. Brodowicz T, Krzakowski M, Zwitter M, et al. Central European Cooperative Oncology Group CECOG. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer. 2006; 52(2): 155–163.
  11. Smith IE, O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol. 2001; 19(5): 1336–1343.
  12. Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol. 2002; 20(5): 1335–1343.
  13. Belani CP, Barstis J, Perry MC, et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol. 2003; 21(15): 2933–2939.
  14. von Plessen C, Bergman B, Andresen O, et al. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer. 2006; 95(8): 966–973.
  15. Westeel V, Quoix E, Moro-Sibilot D, et al. French Thoracic Oncology Collaborative Group (GCOT). Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2005; 97(7): 499–506.
  16. Park JOh, Kim SW, Ahn JS, et al. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol. 2007; 25(33): 5233–5239.
  17. Soon YuY, Stockler MR, Askie LM, et al. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol. 2009; 27(20): 3277–3283.
  18. Jassem J, Drosik K, Dziadziuszko R, et al. Systemowe leczenie niedrobnokomórkowego raka płuca i złośliwego międzybłoniaka opłucnej: uaktualnione zalecenia oparte na wynikach wiarygodnych badań klinicznych. Nowotwory. 2007; 57: 71–78.
  19. Azzoli CG, Baker S, Temin S, et al. American Society of Clinical Oncology. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2009; 27(36): 6251–6266.
  20. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer. 2006; 107(7): 1589–1596.
  21. Cappuzzo F, Coudert BP, Wierzbicki R, et al. Efficacy and safety of erlotinib as first-line maintenance in NSCLC following non-progression with chemotherapy: results from the phase III SATURN study. J Thor Oncol. 2009; 4(supl. 1): 289.
  22. Meerbeeck J.V. A randomized phase III study of follow up with or without adjuvant Gefitinib (Iressa TM) following chemotherapy in patients with advanced non-small cell lung cancer EORTC08021. http://www.eortc.be/protoc/ details.asp?protocol=08021.
  23. INFORM study. http://clinicaltrials.gov.
  24. Lee JS, Ignacio J, Yu C, et al. FAST-ACT: A phase II randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2008; 26(15_suppl): 8031.
  25. Takeda K, Hida T, Sato T, et al. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol. 2010; 28(5): 713–715.
  26. Miller VA, Das A, Rossi M, et al. A randomized, doubleblind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. 2009; 27: LBA8002.
  27. Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008; 26(15): 2450–2456.
  28. Pirker R, Pereira JR, Szczesna A, et al. FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009; 373(9674): 1525–1531.
  29. Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol. 2010; 28(6): 911–917.
  30. O’Byrne K, Bondarenko I, Barrios C, et al. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): data from the FLEX study FLEX. J Clin Oncol. 2009; 27: 15.
  31. Duchnowska R. Inhibitory kinazy tyrozynowej EGFR w leczeniu przerzutów do mózgu w przebiegu niedrobnokomórkowego raka płuca. Onkol Prakt Klin. 2009; 5: 92–98.
  32. Kim JE, Lee DHo, Choi Y, et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer. 2009; 65(3): 351–354.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl